Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration

10.3389/fonc.2013.00093

Saved in:

Bibliographic Details
Main Authors:	Loh, A.H, Brennan, R.C, Lang, W.H, Hickey, R.J, Malkas, L.H, Sandoval, J.A
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Review
Published:	2020
Subjects:	2 morpholino 8 phenylchromone 8 [4 (1 aminocyclobutyl) phenyl] 9 phenyl 1, 2, 4 triazolo [3, 4 f] [1, 6] naphthyridin 3 (2h) one 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one alendronic acid buparlisib cixutumumab cyclophosphamide dactolisib dalotuzumab doxorubicin enzastaurin etoposide everolimus irinotecan lomustine mammalian target of rapamycin perifosine phosphatidylinositol 3 kinase phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase protein kinase B protein tyrosine kinase rapamycin ridaforolimus temozolomide temsirolimus topotecan transcription factor FKHR transcription factor FOXO unclassified drug unindexed drug vinblastine wortmannin apoptosis cancer inhibition cancer recurrence cancer survival cell proliferation child childhood cancer drug dose escalation drug efficacy drug tolerability enzyme inhibition Ewing sarcoma febrile neutropenia gene mutation hematologic disease human mucosa inflammation neuroblastoma nonhuman osteosarcoma phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) protein expression randomized controlled trial (topic) review rhabdomyosarcoma signal transduction single drug dose solid tumor thrombocytopenia
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183186
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183186
record_format	dspace
spelling	sg-nus-scholar.10635-1831862023-09-20T08:36:31Z Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration Loh, A.H Brennan, R.C Lang, W.H Hickey, R.J Malkas, L.H Sandoval, J.A DUKE-NUS MEDICAL SCHOOL 2 morpholino 8 phenylchromone 8 [4 (1 aminocyclobutyl) phenyl] 9 phenyl 1, 2, 4 triazolo [3, 4 f] [1, 6] naphthyridin 3 (2h) one 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one alendronic acid buparlisib cixutumumab cyclophosphamide dactolisib dalotuzumab doxorubicin enzastaurin etoposide everolimus irinotecan lomustine mammalian target of rapamycin perifosine phosphatidylinositol 3 kinase phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase protein kinase B protein tyrosine kinase rapamycin ridaforolimus temozolomide temsirolimus topotecan transcription factor FKHR transcription factor FOXO unclassified drug unindexed drug vinblastine wortmannin apoptosis cancer inhibition cancer recurrence cancer survival cell proliferation child childhood cancer drug dose escalation drug efficacy drug tolerability enzyme inhibition Ewing sarcoma febrile neutropenia gene mutation hematologic disease human mucosa inflammation neuroblastoma nonhuman osteosarcoma phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) protein expression randomized controlled trial (topic) review rhabdomyosarcoma signal transduction single drug dose solid tumor thrombocytopenia 10.3389/fonc.2013.00093 Frontiers in Oncology 43558 Article 00093 2020-11-10T00:28:16Z 2020-11-10T00:28:16Z 2013 Review Loh, A.H, Brennan, R.C, Lang, W.H, Hickey, R.J, Malkas, L.H, Sandoval, J.A (2013). Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration. Frontiers in Oncology 43558 : Article 00093. ScholarBank@NUS Repository. https://doi.org/10.3389/fonc.2013.00093 2234943X https://scholarbank.nus.edu.sg/handle/10635/183186 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	2 morpholino 8 phenylchromone 8 [4 (1 aminocyclobutyl) phenyl] 9 phenyl 1, 2, 4 triazolo [3, 4 f] [1, 6] naphthyridin 3 (2h) one 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one alendronic acid buparlisib cixutumumab cyclophosphamide dactolisib dalotuzumab doxorubicin enzastaurin etoposide everolimus irinotecan lomustine mammalian target of rapamycin perifosine phosphatidylinositol 3 kinase phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase protein kinase B protein tyrosine kinase rapamycin ridaforolimus temozolomide temsirolimus topotecan transcription factor FKHR transcription factor FOXO unclassified drug unindexed drug vinblastine wortmannin apoptosis cancer inhibition cancer recurrence cancer survival cell proliferation child childhood cancer drug dose escalation drug efficacy drug tolerability enzyme inhibition Ewing sarcoma febrile neutropenia gene mutation hematologic disease human mucosa inflammation neuroblastoma nonhuman osteosarcoma phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) protein expression randomized controlled trial (topic) review rhabdomyosarcoma signal transduction single drug dose solid tumor thrombocytopenia
spellingShingle	2 morpholino 8 phenylchromone 8 [4 (1 aminocyclobutyl) phenyl] 9 phenyl 1, 2, 4 triazolo [3, 4 f] [1, 6] naphthyridin 3 (2h) one 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one alendronic acid buparlisib cixutumumab cyclophosphamide dactolisib dalotuzumab doxorubicin enzastaurin etoposide everolimus irinotecan lomustine mammalian target of rapamycin perifosine phosphatidylinositol 3 kinase phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase protein kinase B protein tyrosine kinase rapamycin ridaforolimus temozolomide temsirolimus topotecan transcription factor FKHR transcription factor FOXO unclassified drug unindexed drug vinblastine wortmannin apoptosis cancer inhibition cancer recurrence cancer survival cell proliferation child childhood cancer drug dose escalation drug efficacy drug tolerability enzyme inhibition Ewing sarcoma febrile neutropenia gene mutation hematologic disease human mucosa inflammation neuroblastoma nonhuman osteosarcoma phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) protein expression randomized controlled trial (topic) review rhabdomyosarcoma signal transduction single drug dose solid tumor thrombocytopenia Loh, A.H Brennan, R.C Lang, W.H Hickey, R.J Malkas, L.H Sandoval, J.A Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
description	10.3389/fonc.2013.00093
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Loh, A.H Brennan, R.C Lang, W.H Hickey, R.J Malkas, L.H Sandoval, J.A
format	Review
author	Loh, A.H Brennan, R.C Lang, W.H Hickey, R.J Malkas, L.H Sandoval, J.A
author_sort	Loh, A.H
title	Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
title_short	Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
title_full	Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
title_fullStr	Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
title_full_unstemmed	Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
title_sort	dissecting the pi3k signaling axis in pediatric solid tumors: novel targets for clinical integration
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183186
_version_	1779152955505639424

Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration

Similar Items